Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Reality Check? Granules Moves Out Of China JV

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

Commercial Strategy

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.

Commercial India

Early Indian Promise For A Cut-Price CAR-T Therapy

A faculty member at the Indian Institute of Technology and the founder of Indian venture ImmunoACT hopes to deliver an indigenously developed CAR-T therapy at a fraction of current treatment costs.

Research & Development India

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Biosimilars Commercial

US Biosimilar Market – Who's In It For The Long Haul?

A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?

Commercial Strategy

Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved

India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.
Asia Pacific India
See All
Advertisement
UsernamePublicRestriction

Register